{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:57:50Z","timestamp":1787165870512,"version":"build-2736575974"},"reference-count":135,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ricerca Corrente Grant"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer patients, especially long cancer survivors, are exposed to several cardio-metabolic diseases, including diabetes, heart failure, and atherosclerosis, which increase their risk of cardiovascular mortality. Therapy with glucagon-like peptide 1 (GLP1) receptor agonists demonstrated several beneficial cardiovascular effects, including atherosclerosis and heart failure prevention. Cardiovascular outcome trials (CVOTs) suggest that GLP-1 RA could exert cardiorenal benefits and systemic anti-inflammatory effects in patients with type-2 diabetes through the activation of cAMP and PI3K\/AkT pathways and the inhibition of NLRP-3 and MyD88. In this narrative review, we highlight the biochemical properties of GLP-1 RA through a deep analysis of the clinical and preclinical evidence of the primary prevention of cardiomyopathies. The overall picture of this review encourages the study of GLP-1 RA in cancer patients with type-2 diabetes, as a potential primary prevention strategy against heart failure and atherosclerosis.<\/jats:p>","DOI":"10.3390\/ijms252011299","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T03:57:09Z","timestamp":1729483029000},"page":"11299","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-5401","authenticated-orcid":false,"given":"Vincenzo","family":"Quagliariello","sequence":"first","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Canale","sequence":"additional","affiliation":[{"name":"U.O.C. Cardiologia, Ospedale Versilia, 55041 Lido di Camaiore, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-0695","authenticated-orcid":false,"given":"Irma","family":"Bisceglia","sequence":"additional","affiliation":[{"name":"Servizi Cardiologici Integrati, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, 00148 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-4098","authenticated-orcid":false,"given":"Martina","family":"Iovine","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vienna","family":"Giordano","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Scherillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hospital San Pio Benevento (BN), 82100 Benevento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-0527","authenticated-orcid":false,"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"U.O.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Maurea","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Salerno, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Barbato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-6908","authenticated-orcid":false,"given":"Alessandro","family":"Inno","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar di Valpolicella, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-9148","authenticated-orcid":false,"given":"Massimiliano","family":"Berretta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0315-3304","authenticated-orcid":false,"given":"Andrea","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Cardiology Unit of Emergency Department, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Oliva","sequence":"additional","affiliation":[{"name":"UOSD Cardiologia di Interesse Oncologico IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3130-0079","authenticated-orcid":false,"given":"Alessandra","family":"Greco","sequence":"additional","affiliation":[{"name":"Divisione di Cardiologia, Fondazione IRCCS San Matteo Hospital, Viale Golgi 19, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-0092","authenticated-orcid":false,"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00325481.2020.1798099","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes: Role and clinical experience to date","volume":"132","author":"Brunton","year":"2020","journal-title":"Postgrad. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","article-title":"Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus","volume":"76","author":"Guyton","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists [GLP-1 RA] in Diabetes-Related Neurodegenerative Diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: An updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1331\/JAPhA.2009.09078","article-title":"Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors","volume":"49","author":"Neumiller","year":"2009","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yeh, T.L., Tsai, M.C., Tsai, W.H., Tu, Y.K., and Chien, K.L. (2023). Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0278685"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/jdi.13749","article-title":"Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type\u20092 diabetes: A randomized, open-label trial study","volume":"13","author":"Takeshita","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"524517","DOI":"10.1155\/2014\/524517","article-title":"The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: Tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp","volume":"2014","author":"Wu","year":"2014","journal-title":"J. Diabetes Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_13","first-page":"T1","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS","volume":"221","author":"Ijzerman","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Aparecida Silveira, E., Vaseghi, G., de Carvalho Santos, A.S., Kliemann, N., Masoudkabir, F., Noll, M., Mohammadifard, N., Sarrafzadegan, N., and de Oliveira, C. (2020). Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239042"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Crudele, L., Piccinin, E., and Moschetta, A. (2021). Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis. Nutrients, 13.","DOI":"10.3390\/nu13062101"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40256-024-00647-3","article-title":"Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials","volume":"24","author":"Balieiro","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41366-023-01254-z","article-title":"Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment","volume":"47","author":"Stenberg","year":"2023","journal-title":"Int. J. Obes."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13300-021-01198-5","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations","volume":"13","author":"Romera","year":"2022","journal-title":"Diabetes Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","article-title":"New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling","volume":"432","author":"Tomas","year":"2020","journal-title":"J. Mol. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/hh1701.095716","article-title":"Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes","volume":"89","author":"Egan","year":"2001","journal-title":"Circ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellsig.2009.09.032","article-title":"New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 [GLP-1]","volume":"22","author":"Yu","year":"2010","journal-title":"Cell Signal."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.peptides.2018.07.001","article-title":"GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K\/Akt pathway in a GLP-1 receptor-dependent manner","volume":"106","author":"Liu","year":"2018","journal-title":"Peptides"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2174\/1573399816666200522214554","article-title":"Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review","volume":"16","author":"Elnour","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Caruso, I., Cignarelli, A., Sorice, G.P., Natalicchio, A., Perrini, S., Laviola, L., and Giorgino, F. (2022). Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Metabolites, 12.","DOI":"10.3390\/metabo12020183"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs. other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: A large population-based matched cohort study","volume":"67","author":"Krishnan","year":"2024","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3949\/ccjm.89a.21110","article-title":"The role of GLP-1 receptor agonists in managing type 2 diabetes","volume":"89","author":"Nachawi","year":"2022","journal-title":"Cleve Clin. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jcpt.13230","article-title":"A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents","volume":"45","author":"Cornell","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cmet.2023.01.004","article-title":"The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes","volume":"35","author":"Thomas","year":"2023","journal-title":"Cell Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.diabet.2013.09.004","article-title":"Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus","volume":"39","author":"Owens","year":"2013","journal-title":"Diabetes Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis","volume":"65","author":"Reheman","year":"2016","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kaneto, H., Kimura, T., Shimoda, M., Obata, A., Sanada, J., Fushimi, Y., Nakanishi, S., Mune, T., and Kaku, K. (2021). Favorable Effects of GLP-1 Receptor Agonist against Pancreatic \u03b2-Cell Glucose Toxicity and the Development of Arteriosclerosis: \u201cThe Earlier, the Better\u201d in Therapy with Incretin-Based Medicine. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157917"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1463-1326.2009.01073.x","article-title":"The effects of glucagon-like peptide-1 on the beta cell","volume":"11","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","article-title":"GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK","volume":"63","author":"Beiroa","year":"2014","journal-title":"Diabetes"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hropot, T., Herman, R., Janez, A., Lezaic, L., and Jensterle, M. (2023). Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108592"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"R708","DOI":"10.1152\/ajpregu.00068.2018","article-title":"Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats","volume":"315","author":"Krieger","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","article-title":"GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1","volume":"59","author":"Xu","year":"2016","journal-title":"Diabetologia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"bvaa037","DOI":"10.1210\/jendso\/bvaa037","article-title":"Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM","volume":"4","author":"McKee","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MNH.0000000000000976","article-title":"Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression","volume":"33","author":"Holliday","year":"2024","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.3390\/cimb45080420","article-title":"Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications","volume":"45","author":"Caturano","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12020-016-1168-2","article-title":"Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: A systematic review and meta-analysis","volume":"55","author":"He","year":"2017","journal-title":"Endocrine"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Canale, M.L., Bisceglia, I., Maurea, C., Gabrielli, D., Tarantini, L., Paccone, A., Inno, A., Oliva, S., and Cadeddu Dessalvi, C. (2024). Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081650"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"300060521992981","DOI":"10.1177\/0300060521992981","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway","volume":"49","author":"Chen","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Diz-Chaves, Y., Mastoor, Z., Spuch, C., Gonz\u00e1lez-Mat\u00edas, L.C., and Mallo, F. (2022). Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179583"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bollyky, P.L., Bice, J.B., Sweet, I.R., Falk, B.A., Gebe, J.A., Clark, A.E., Gersuk, V.H., Aderem, A., Hawn, T.R., and Nepom, G.T. (2009). The toll-like receptor signaling molecule Myd88 contributes to pancreatic beta-cell homeostasis in response to injury. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005063"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14336\/AD.2021.0928","article-title":"Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases","volume":"13","author":"Peng","year":"2022","journal-title":"Aging Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function","volume":"31","author":"Timper","year":"2020","journal-title":"Cell Metab."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Shen, R., Qin, S., Lv, Y., Liu, D., Ke, Q., Shi, C., Jiang, L., Yang, J., and Zhou, Y. (2024). GLP-1 receptor agonist attenuates tubular cell ferroptosis in diabetes via enhancing AMPK-fatty acid metabolism pathway through macropinocytosis. Biochim. Biophys. Acta Mol. Basis Dis., 1870.","DOI":"10.1016\/j.bbadis.2024.167060"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eabn8017","DOI":"10.1126\/scisignal.abn8017","article-title":"Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis","volume":"15","author":"Abe","year":"2022","journal-title":"Sci. Signal."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Canale, M.L., Bisceglia, I., Iovine, M., Paccone, A., Maurea, C., Scherillo, M., Merola, A., Giordano, V., and Palma, G. (2024). Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-\u03baB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1289663"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101922","DOI":"10.1016\/j.clinre.2022.101922","article-title":"The mTORC1\/AMPK pathway plays a role in the beneficial effects of semaglutide [GLP-1 receptor agonist] on the liver of obese mice","volume":"46","author":"Marinho","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Faria, S.S., Costantini, S., de Lima, V.C.C., de Andrade, V.P., Rialland, M., Cedric, R., Budillon, A., and Magalh\u00e3es, K.G. (2021). NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J. Biomed. Sci., 28.","DOI":"10.1186\/s12929-021-00724-8"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","article-title":"GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: Mechanism and glucose dependence","volume":"15","author":"Meloni","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1007\/s00125-015-3651-3","article-title":"Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice","volume":"58","author":"Heppner","year":"2015","journal-title":"Diabetologia"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Liao, C., Liang, X., Zhang, X., and Li, Y. (2023). The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0289616"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/JOE-18-0374","article-title":"The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution","volume":"240","author":"Zhao","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Liu, F., Yang, Q., Zhang, H., Zhang, Y., Yang, G., Ban, B., Li, Y., and Zhang, M. (2022). The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270899"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., and Madej, P. (2022). The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084334"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10557-020-07032-7","article-title":"LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: The National Health and Nutrition Examination Surveys 2007\u20132016","volume":"34","author":"Fan","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_67","first-page":"28S","article-title":"I risultati dello studio LEADER: Evidenze attuali e prospettive di ricerca [Results of the LEADER study: Current evidence and perspectives in research]","volume":"17","author":"Mannucci","year":"2016","journal-title":"G. Ital. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10157-020-02007-2","article-title":"Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats","volume":"25","author":"Yamada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Aldhaleei, W.A., Abegaz, T.M., and Bhagavathula, A.S. (2024). Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals, 17.","DOI":"10.3390\/ph17020199"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: A systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-Like Peptide-1 Receptor Agonists across the Spectrum of Heart Failure","volume":"109","author":"Ferreira","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/dom.15529","article-title":"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression","volume":"26","author":"Rivera","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: A randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Drucker, D.J. (2024). Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care, ahead of print.","DOI":"10.2337\/dci24-0003"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/DMSO.S193693","article-title":"Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data","volume":"13","author":"Chudleigh","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of Once-Weekly Exenatide in Patients with Type 2 Diabetes Mellitus with and Without Heart Failure and Heart Failure-Related Outcomes: Insights from the EXSCEL Trial","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and Cardiovascular Outcomes according to Renal Function in Patients Treated with Once-Weekly Exenatide: Insights from the EXSCEL Trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 Receptor Agonist Discontinuation among Patients with Obesity and\/or Type 2 Diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.037775","article-title":"Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6","volume":"53","author":"Strain","year":"2022","journal-title":"Stroke"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1574886315999201208212356","article-title":"Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues","volume":"16","author":"Iqbal","year":"2021","journal-title":"Curr. Drug Saf."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-023-01793-9","article-title":"The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","volume":"22","author":"Lin","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/phar.2737","article-title":"Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis","volume":"42","author":"Kelly","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hu, E.H., Tsai, M.L., Lin, Y., Chou, T.S., and Chen, T.H. (2024). A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists. Medicina, 60.","DOI":"10.3390\/medicina60030357"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100682","DOI":"10.1016\/j.ajpc.2024.100682","article-title":"GLP-1 RA for cardiometabolic risk reduction in obesity\u2014How do we best describe benefit and value?","volume":"18","author":"Kumar","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients with Obesity HFpEF Phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"ehae322","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure with Preserved Ejection Fraction: STEP-HFpEF Trials","volume":"84","author":"Verma","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Verma, S., Petrie, M.C., Borlaug, B.A., Butler, J., Davies, M.J., Kitzman, D.W., Shah, S.J., R\u00f6nnb\u00e4ck, C., Abildstr\u00f8m, S.Z., and Liisberg, K. (2024). Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program. J. Am. Coll. Cardiol., ahead of print.","DOI":"10.1016\/j.jacc.2024.08.028"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: A prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program","volume":"84","author":"Petrie","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10741-024-10408-8","article-title":"STEP HFpEF DM: A sweet sequel","volume":"29","author":"Harrington","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Aslam, B., Bin Zafar, M.D., Changez, M.I.K., Abdullah, M., Safwan, M., Qamar, B., Shinwari, A., and Rai, S. (2023). Exploring the potential impact of GLP-1 receptor agonists in cancer therapy. Minerva Endocrinol., ahead of print.","DOI":"10.23736\/S2724-6507.23.04101-5"},{"key":"ref_108","first-page":"357","article-title":"GLP-1 receptor agonist as treatment for cancer as well as diabetes: Beyond blood glucose control","volume":"11","author":"Nomiyama","year":"2016","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients with Type 2 Diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients with Type 2 Diabetes, with and without Overweight\/Obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: Data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e3574","DOI":"10.1002\/dmrr.3574","article-title":"GLP-1 receptor agonist use during hospitalisation: Better glycaemic control compared to premixed insulin","volume":"38","author":"Jervis","year":"2022","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Vulcan, A., Manjer, J., and Ohlsson, B. (2017). High blood glucose levels are associated with higher risk of colon cancer in men: A cohort study. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3874-4"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1007\/s00520-022-07442-3","article-title":"Hyperglycemia, symptoms, and symptom clusters in colorectal cancer survivors with type 2 diabetes","volume":"30","author":"Storey","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e2350408","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients with Type 2 Diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/curroncol30010005","article-title":"The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review","volume":"30","author":"George","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e13088","DOI":"10.1111\/obr.13088","article-title":"Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence","volume":"22","author":"Silveira","year":"2021","journal-title":"Obes. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: A systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Dong, S., Wang, Z., Shen, K., and Chen, X. (2021). Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.629666"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00125-012-2793-9","article-title":"Incidence of diabetes among postmenopausal breast cancer survivors","volume":"56","author":"Lipscombe","year":"2013","journal-title":"Diabetologia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2174\/156800961506150805145120","article-title":"Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety","volume":"15","author":"Azoury","year":"2015","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/clinpract13010003","article-title":"The Role of Immune Checkpoint Inhibitors in Cancer Therapy","volume":"13","author":"Basudan","year":"2022","journal-title":"Clin. Pract."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Tamai, Y., Fujiwara, N., Tanaka, T., Mizuno, S., and Nakagawa, H. (2023). Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15205072"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2019.05.028","article-title":"Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab","volume":"292","author":"Quagliariello","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Quagliariello, V., Passariello, M., Di Mauro, A., Cipullo, C., Paccone, A., Barbieri, A., Palma, G., Luciano, A., Buccolo, S., and Bisceglia, I. (2022). Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.930797"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Libby, P. (2021). Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond. Cells, 10.","DOI":"10.3390\/cells10040951"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5568159","DOI":"10.1155\/2021\/5568159","article-title":"Effect of GLP-1\/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Mediators Inflamm."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Hachu\u0142a, M., Kosowski, M., Ryl, S., Basiak, M., and Okopie\u0144, B. (2024). Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031854"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/20\/11299\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:15Z","timestamp":1760113035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/20\/11299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":135,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms252011299"],"URL":"https:\/\/doi.org\/10.3390\/ijms252011299","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}